PFE  Pfizer Inc.

Exchange

NYSE

Sector

Consumer Durables

Industry

Major Pharmaceuticals

Market Cap.

196.9B

Vuru Grade

72.50/100

Current Price

$31.25
-0.58 (-1.82%)

Growth Price

$30.64
Fairly valued

Stability Price

$11.67
Overvalued by 62.65%

Company Metrics

  • 22.46 P/E
  • 4.04 P/S
  • 2.57 P/B
  • 1.417 EPS
  • 11.61% Cash ROIC
  • 1.39 Cash Ratio
  • 1.04 / 3.27 % Dividend
  • 25.21M Avg. Vol.
  • 6.30B Shares
  • 196.9B Market Cap.

Company Description

Pfizer Inc., a biopharmaceutical company, offers prescription medicines for humans and animals worldwide. The company's Biopharmaceutical segment's provides Lipitor for elevated LDL-cholesterol levels in the blood; Enbrel for rheumatoid arthritis, polyarticular juvenile rheumatoid arthritis, psoriatic arthritis, plaque psoriasis, and ankylosing spondylitis; Lyrica for post-herpetic neuralgia, diab...
more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

Pfizer Inc. (PFE) Terminates $70 Million Deal With Repligen Corporation (RGEN)
Bidness ETC - 7 hours ago
Pfizer Inc. (NYSE:PFE) announced Friday its decision to terminate the $70 million collaboration deal with Repligen Corporation (NASDAQ:RGEN) for developing treatments for spinal muscular atrophy (SMA), returning some early stage treatments to Repligen.
Moving On From Pfizer's 2009 Dividend Cut
Seeking Alpha (registration) - 17 hours ago
There's a lot to like about Pfizer (NYSE:PFE). For one, the company sports a 3.5% dividend yield, and growth in the payout is back after the firm cut the dividend to finance the Wyeth transaction back in 2009.
The One Thing Pfizer, Inc. Shareholders Should Worry About, and One They ...
Motley Fool - Jan 28, 2015
Pfizer (NYSE: PFE ) , the largest pharmaceutical company in the world by revenue, is growing more predictable by the day.
Pfizer's 2015 forecast disappoints, crimped by generics, dollar - Reuters
PFIZER INC (PFE) Earnings Report: Q4 2014 Conference Call Transcript
TheStreet.com - Jan 27, 2015
Good day, everyone, and welcome to Pfizer's Fourth-Quarter 2014 Earnings conference call. Today's call is being recorded.
PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2014 RESULTS ... - Business Wire (press release)
Pfizer, Inc. Should Forget AstraZeneca and Buy This Company Instead
Motley Fool - Jan 27, 2015
Pfizer Inc.'s (NYSE: PFE ) failed bid to acquire U.K.-based AstraZeneca (NYSE: AZN ) last year suggests that dealmakers are hard at work identifying new acquisition targets for the global drugmaker.
Pfizer to pay $400 million to avert investor class action trial
Reuters - Jan 27, 2015
"This resolution reflects a desire by the company to avoid the distraction of continued litigation and focus on the needs of patients and physicians," said Christine Regan Lindenbloom, a Pfizer spokeswoman. Michael Dowd, a lawyer for the investors at ...
Does Pfizer Inc. Stock Offer a Market-Crushing Opportunity in 2015?
Motley Fool - Jan 6, 2015
The first step was the IPO of Pfizer's animal health business that gave rise to Zoetis (NYSE: ZTS ) in June 2013. That move cleared the way for the next step, namely reorganizing the company into three operational units: global innovative ...
Pfizer's $33 Billion Cash Pile Has Everyone Guessing
Bloomberg - Jan 26, 2015
After the AstraZeneca deal fell apart, Pfizer approached Actavis Plc (ACT), people familiar with the matter said last year.
Pfizer Inc., Procter & Gamble Co Edge Out Earnings Estimates
ValueWalk - Jan 27, 2015
Pfizer and Procter & Gamble released their latest quarter earnings reports before opening bell this morning. Pfizer posted adjusted earnings of 54 cents per share on $13.1 billion in revenue. Analysts had been expecting the drug maker to post earnings ...
Earnings: AT&T, Pfizer, Procter & Gamble, DuPont, Caterpillar, 3M, and Apple - Richmond.com
Pfizer Will Do Fine Without AstraZeneca
Barron's - Jan 28, 2015
Their opinions in no way represent those of Barrons.com or Dow Jones & Company, Inc. Some of the reports' issuers have provided, or hope to provide, investment-banking or other services to the companies being analyzed.